title: Mechanism of caspase-2 activation upon DNA damage.
abstract: The mechanism of caspase-2 activation in response to DNA damage was studied using human ovarian cancer cells Caov-4 treated with chemotherapeutic agent cisplatin. It was shown that mutations of the three cleavage sites of caspase-2 do not affect the assembly of the macromolecular complex of caspase-2 and its activation, but, conversely, stabilize this complex, most likely, via the inhibition of the dissociation of the active caspase-2.
authors.affiliation: Faculty of Basic Medicine, Lomonosov Moscow State University, Lomonosovsky pr. 31/5, 119991, Moscow, Russia.
authors.forename: V I
authors.initials: VI
authors.lastname: Aksenova
authors.affiliation: Faculty of Basic Medicine, Lomonosov Moscow State University, Lomonosovsky pr. 31/5, 119991, Moscow, Russia. gelina@rambler.ru.
authors.forename: G S
authors.initials: GS
authors.lastname: Kopeina
authors.affiliation: Faculty of Basic Medicine, Lomonosov Moscow State University, Lomonosovsky pr. 31/5, 119991, Moscow, Russia.
authors.forename: A V
authors.initials: AV
authors.lastname: Zamaraev
authors.affiliation: Faculty of Basic Medicine, Lomonosov Moscow State University, Lomonosovsky pr. 31/5, 119991, Moscow, Russia.|Department of Translational Inflammation, Institute of Experimental Internal Medicine, Otto von Guericke University, Magdeburg, Germany.
authors.forename: B D
authors.initials: BD
authors.lastname: Zhivotovsky
authors.affiliation: Faculty of Basic Medicine, Lomonosov Moscow State University, Lomonosovsky pr. 31/5, 119991, Moscow, Russia.|Department of Translational Inflammation, Institute of Experimental Internal Medicine, Otto von Guericke University, Magdeburg, Germany.
authors.forename: I N
authors.initials: IN
authors.lastname: Lavrik
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D015153:Blotting, Western; D053420:CRADD Signaling Adaptor Protein / Q000378:metabolism; D053143:Caspase 2 / Q000235:genetics / Q000378:metabolism*; D061945:Caspase Inhibitors / Q000494:pharmacology; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology; D003546:Cysteine Endopeptidases / Q000235:genetics / Q000378:metabolism*; D004249:DNA Damage / Q000187:drug effects / Q000502:physiology*; D053418:Death Domain Receptor Signaling Adaptor Proteins / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D049452:Green Fluorescent Proteins / Q000235:genetics / Q000378:metabolism; D057809:HEK293 Cells; D006801:Humans; D047468:Immunoprecipitation; D009154:Mutation; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000201:enzymology; D059748:Proteolysis; D014162:Transfection
chemical_list: D000970:Antineoplastic Agents; D053420:CRADD Signaling Adaptor Protein; C104252:CRADD protein, human; D061945:Caspase Inhibitors; D053418:Death Domain Receptor Signaling Adaptor Proteins; C485896:PIDD1 protein, human; D049452:Green Fluorescent Proteins; C490360:CASP2 protein, human; D053143:Caspase 2; D003546:Cysteine Endopeptidases; D002945:Cisplatin